Why the study?
The molecular regulators governing cardiac fibroblast activation after MI remain incompletely understood, and the role of LMCD1 in cardiac fibrosis is unknown.
Does LMCD1 silencing reduce cardiac fibrosis and improve cardiac function post-myocardial infarction in preclinical models?
Population
Mice subjected to LAD artery ligation and TGF-β1-stimulated primary cardiac fibroblasts
Comparison
LMCD1 silencing or overexpression vs controls
Design
Preclinical animal and in vitro mechanistic study
Key result
LMCD1 silencing improved cardiac function and reduced fibrotic area in a mouse model of myocardial infarction by inhibiting STAT5A activation in cardiac fibroblasts.
Authors
Loading...
Hypothesis-generating for LMCD1 targeting in post-MI fibrosis; extends its profibrotic role from kidney/lung and requires validation before clinical use.
Does LMCD1 silencing reduce cardiac fibrosis and improve cardiac function post-myocardial infarction in preclinical models?
LMCD1 is identified as a novel driver of post-MI cardiac fibrosis through STAT5A activation, suggesting it may be a potential target for anti-fibrotic therapy.
Kang et al. (2026) studied Cardiac fibrosis post-myocardial infarction. LMCD1 silencing was evaluated on Cardiac function and fibrotic area. LMCD1 silencing improved cardiac function and reduced fibrotic area in a mouse model of myocardial infarction by inhibiting STAT5A activation in cardiac fibroblasts.